SANCUSO can be worn
for 7 days.

Your patients need to endure chemo.
But now they don’t have to endure nausea and vomiting

A better way to help your patients avoid CINV

You’re an oncology nurse, so you know all about the difficulties of managing CINV with conventional options: oral medications or IVs.

But we want to make sure you are fully aware of SANCUSO and its many advantages.

SANCUSO (Granisetron Transdermal System) — the first and only patch for the prevention for CINV¹

Apply patch to the outside part of the upper arm
Continous delivery of granisetron for complete control
Can be worn for 7 days, which gives 5 days of continuous CINV prevention
Simple to use
Proven effective with treatments for breast cancer, gastrointestinal cancers, head and neck cancers, and gynecological cancers

Please share your knowledge and experience

At ProStrakan, we are dedicated to doing everything possible to help cancer patients avoid CINV.

You see those patients every day, and we would like to learn whatever you could teach us about managing CINV.

We would greatly appreciate if you could take a few minutes to fill out the short questionnaire below.

IMPORTANT SAFETY INFORMATION
SANCUSO^® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.¹ SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.¹ Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.¹ Mild application site reactions have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.¹ Patients should avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.¹ The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).¹ SANCUSO contains granisetron.¹ Healthcare professionals should avoid prescribing any additional products that contain granisetron. No clinically relevant drug interactions have been reported in clinical studies with SANCUSO.¹

Your patients need to endure chemo. But now they don’t have to endure nausea and vomiting

A better way to help your patients avoid CINV

SANCUSO (Granisetron Transdermal System) — the first and only patch for the prevention for CINV1

Please share your knowledge and experience

Your patients need to endure chemo.
But now they don’t have to endure nausea and vomiting

SANCUSO (Granisetron Transdermal System) — the first and only patch for the prevention for CINV¹